<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578811</url>
  </required_header>
  <id_info>
    <org_study_id>SK-MS10_GID_II_2010</org_study_id>
    <nct_id>NCT01578811</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Assess the Efficacy and Safety of SK-MS10 in subjects With
      acute and chronic gastritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rates of erosive gastritis according to the sydney classification</measure>
    <time_frame>Change from Baseline in the grade of erosive gastritis at 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing rates of erosive gastritis according to the sydney classification</measure>
    <time_frame>Change from Baseline in the grade of gastric erosions at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rates of erosive gastritis by estimated the number of erosion</measure>
    <time_frame>Change from Baseline in the number of gastric erosions at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing rates of edema according to the sydney classification</measure>
    <time_frame>Change from Baseline in the grade of edema at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rates of erythema according to the sydney classification</measure>
    <time_frame>Change from Baseline in the grade of erythema at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rates of hemorrhage according to the Scandinavian Journal of Gastroenterology - Supplement</measure>
    <time_frame>Change from Baseline in the grade of hemorrhage at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rates of symptoms using Korean NDI</measure>
    <time_frame>Questionaire at baseline and then week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Erosive Gastritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SK-MS10 160mg t.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SK-MS10 320mg t.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SK-MS10</intervention_name>
    <description>Dosage</description>
    <arm_group_label>SK-MS10 160mg t.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SK-MS10</intervention_name>
    <description>Dosage</description>
    <arm_group_label>SK-MS10 320mg t.i.d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have been diagnosed as erosive gastritis by endoscopy within 1 weeks before
             enrollment.

          2. Patients who voluntarily signed written informed consent may participate in the study.

        Exclusion Criteria:

          1. Pregnant or lactating female.

          2. Patients have gastric ulcer, duodenal ulcer and GERD.

          3. Use of any proton pump inhibitor, H2-receptor antagonist, muscarine receptor
             antagonist and gastrin receptor antagonist within 2 weeks before initiating study drug
             therapy

          4. Patients requiring corticosteroid therapy

          5. Severe neurological or psychological disease

          6. History of allergic reaction to the medications used in this study

          7. Use of other investigational drugs within 30 days prior to the study.

          8. Patients that investigators consider ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SKChemicals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

